Crone J, Rami B, Huber W D, Granditsch G, Schober E
Children's Hospital, University of Vienna, Austria.
J Pediatr Gastroenterol Nutr. 2003 Jul;37(1):67-71. doi: 10.1097/00005176-200307000-00011.
The prevalence of celiac disease (CD) in children with diabetes mellitus type 1 (DM) is significantly higher than in the nondiabetic population. Most patients with DM and associated CD do not experience typical gastrointestinal symptoms of CD. There is no agreement on the necessity of screening and management of silent CD for patients with DM or on the time scale for screening. Only few data on follow-up evaluation of children with DM and CD-related antibodies are available.
One hundred fifty-seven patients with DM (mean age, 14.8 years; range, 4-21 years; male, 83) were screened with endomysial antibodies (EMA) between 1993 and 2001. A follow-up period of at least 3 years, with at least 2 EMA measurements, was possible. Group 1 comprised 37 patients whose first measurement was at the onset of DM. Group 2 comprised 120 patients whose first measurement was during the course of the disease. In patients with positive EMA, small bowel biopsy was performed. Thyroid peroxidase (TPO), thyroglobulin (TgA), glutamate decarboxylase (GAD), antiinsulin (IAA), and islet cell antibodies (IA2) were measured in all patients.
EMA was positive in 16 patients, in 5 at onset of DM and in 11 during the course of DM (mean duration, 33.6 months; range, 11-105 months). Biopsy results showed normal mucosa in seven patients, increased intraepithelial lymphocyte counts in one, and flat mucosa in eight. There was no significant difference between EMA-positive and EMA-negative patients regarding height, weight, HbA1c level, frequency of hypoglycemia or hyperglycemia, TPO, TgA, GAD, IAA, or IA2.
This study emphasizes the high prevalence of CD in patients with DM. Although several patients already had positive EMA titers at the onset of DM, seroconversion may also occur during the course of the disease. Screening for CD with EMA or tissue transglutaminase should be included in the initial investigation of DM, but should also be repeated over time to detect late seroconversion.
1型糖尿病(DM)患儿中乳糜泻(CD)的患病率显著高于非糖尿病人群。大多数DM合并CD的患者没有CD典型的胃肠道症状。对于DM患者无症状CD的筛查和管理的必要性或筛查的时间范围尚无共识。关于DM和CD相关抗体患儿的随访评估仅有少量数据。
1993年至2001年间,对157例DM患者(平均年龄14.8岁;范围4 - 21岁;男性83例)进行了肌内膜抗体(EMA)筛查。随访期至少3年,至少进行2次EMA检测。第1组包括37例首次检测在DM发病时的患者。第2组包括120例首次检测在疾病过程中的患者。EMA阳性的患者进行小肠活检。对所有患者检测甲状腺过氧化物酶(TPO)、甲状腺球蛋白(TgA)、谷氨酸脱羧酶(GAD)、抗胰岛素(IAA)和胰岛细胞抗体(IA2)。
16例患者EMA呈阳性,其中5例在DM发病时呈阳性,11例在疾病过程中呈阳性(平均病程33.6个月;范围11 - 105个月)。活检结果显示,7例患者黏膜正常,1例上皮内淋巴细胞计数增加,8例黏膜扁平。EMA阳性和EMA阴性患者在身高、体重、糖化血红蛋白水平、低血糖或高血糖发生频率、TPO、TgA、GAD、IAA或IA2方面无显著差异。
本研究强调了DM患者中CD的高患病率。尽管部分患者在DM发病时EMA滴度已呈阳性,但血清转化也可能在疾病过程中发生。DM的初始检查应包括用EMA或组织转谷氨酰胺酶筛查CD,但也应随时间重复检测以发现晚期血清转化。